Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Journal of Clinical & Experimental OncologyISSN: 2324-9110
Shinji Atagi Author
Subjects of specialization
Affiliation
Mucoepidermoid carcinoma, Cancer chemotherapy, Prostate biomarker, Endometrial cancer
Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Nagasone-cho 1180, Kita-ku, Sakai City, Osaka 591-8555, Japan
Biography
Shinji Atagi was working in the Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Nagasone-cho 1180, Kita-ku, Sakai City, Osaka 591-8555, Japan. He has more than 40 publications. His current research area related to osteoarthropathy
Publications
Research Article Open Access
Comparing Gefitinib and Erlotinib With Regard To Brain Metastases Recurrence in EGFR-Mutant Non-Small Cell Lung Cancer Patients
Author(s): Kenji Nakahama, Akihiro Tamiya, Yoshihiko Taniguchi, Yoko Naoki, Masaki Kanazu and Shinji Atagi
Brain metastases of lung cancer are associated with a poor prognosis. Little research has been conducted to directly compare erlotinib with gefitinib regarding the frequency of central nerve system recurrence. This is the first study to directly compare erlotinib with gefitinib in terms of brain metastases recurrence rates in patients with EGFR-mutant NSCLC who had no brain metastasis at the time of starting TKI treatment. This was a single-center retrospective study. Advanced or recurrent non-small cell lung cancer patients with no brain metastases at the time of starting initial tyrosine kinase inhibitor treatment who received either gefitinib or erlotinib monotherapy were selected. The primary endpoint was the incidence of brain metastases, and secondary ... view more»
Google Scholars / Researchers Sites
